Nanology Labs is an early-stage pharmaceutical company developing theranostic agents (MRI contrast agent/Radio-sensitizer) for cancer detection and therapy. Nanology Labs has designed and is developing Manganescan® that allows detection of tumors at early stages using MRI. Simultaneously, it sensitizes cancer cells which improves radiation therapy outcomes. The agent is 3x more sensitive than current Gadolinium contrast agents (GBCAs), and can cross the blood-brain barrier; this enables early and precise detection and targeting of brain cancer. Manganescan produces oxygen molecules when localized in the tumor, by which enhances radiation therapy efficacy and improves the patients' life expectancy by more than 5-fold.
Direct poster presentation link is here https://www.synapselifescience.com/competition?wix-vod-video-id=2e6d3b44f7d446d9a74722984fd12f49&wix-vod-comp-id=comp-k7xqqo031
Thanks, Richard, for the question. Yes, We have three IP covering the technology. One is issued and two are in international phase.